skip to content

Cambridge Academy of Therapeutic Sciences

Read more at: MPhil in Therapeutic Sciences

MPhil in Therapeutic Sciences

The University of Cambridge and The Cambridge Academy of Therapeutic Sciences are delighted to launch the new and innovative MPhil in Therapeutic Sciences in Autumn 2018, with the first cohort of students due to begin in Autumn 2019. This one-year full-time course will select a cohort of students with the skills...

Read more

Read more at: WT Developing Concept Fund and MRC Confidence in Concept fund

WT Developing Concept Fund and MRC Confidence in Concept fund

WT Developing Concept Fund and MRC Confidence in Concept fund CATS and OTR invite you to submit applications for internal pump-priming funding for biomedical translational research. The MRC Confidence in Concept fund is intended to accelerate the transition from discovery research to translational development projects by...

Read more


Read more at: Industry Experts in Residence (EiRs)

Industry Experts in Residence (EiRs)

Our Industry Experts in Residence are available to University of Cambridge staff for: Advice on the applicability of specific ideas to drug discovery, diagnostics & devices Advice on translational grant applications Discussions about progression of current translational research projects Work in conjunction with...

Read more

Read more at: New approach to drug discovery could lead to personalised treatment of neuropsychiatric disorders

New approach to drug discovery could lead to personalised treatment of neuropsychiatric disorders

9 May 2019

Researchers have developed a method that could drastically accelerate the search for new drugs to treat mental health disorders such as schizophrenia. Psychiatric disorders are increasingly recognised as disorders of the whole body Sabine Bahn Mental health disorders are the leading cause of disability worldwide...

Read more


Read more at: Cambridge spin-out PolyProx Therapeutics raises £3.4m seed financing

Cambridge spin-out PolyProx Therapeutics raises £3.4m seed financing

2 May 2019

PolyProx Therapeutics, a new biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announced that it has raised £3.4m of seed capital. A spin-out of the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a...

Read more

Read more at: ‘Fingerprint database’ could help scientists to identify new cancer culprits

‘Fingerprint database’ could help scientists to identify new cancer culprits

30 April 2019

Scientists in Cambridge and London have developed a catalogue of DNA mutation ‘fingerprints’ that could help doctors pinpoint the environmental culprit responsible for a patient’s tumour – including showing some of the fingerprints left in lung tumours by specific chemicals found in tobacco smoke. Mutational signatures...

Read more


Read more at: Discovery of genetic variants that protect against obesity and type 2 diabetes could lead to new weight loss medicines

Discovery of genetic variants that protect against obesity and type 2 diabetes could lead to new weight loss medicines

30 April 2019

Around four million people in the UK carry genetic variants that protect them from obesity, type 2 diabetes and heart disease, suggests new research from the University of Cambridge. The team say the discovery could lead to the development of new drugs that help people lose weight. This study drives home the fact that...

Read more

Read more at: Blood pressure drug shows promise for treating Parkinson’s and dementia in animal studies

Blood pressure drug shows promise for treating Parkinson’s and dementia in animal studies

30 April 2019

A prescription drug to treat high blood pressure has shown promise against conditions such as Parkinson’s, Huntington’s and forms of dementia in studies carried out in mice and zebrafish at the University of Cambridge. The drug will need to be tested in patients to see if it has the same effects in humans as it does in...

Read more


Read more at: HIV remission achieved in second patient

HIV remission achieved in second patient

7 March 2019

A second person has experienced sustained remission from HIV-1 after ceasing treatment, according to a study published today in Nature. At the moment the only way to treat HIV is with medications that suppress the virus, which people need to take for their entire lives, posing a particular challenge in developing countries...

Read more

Read more at: Wren Therapeutics secures £18 million in funding to tackle protein misfolding diseases

Wren Therapeutics secures £18 million in funding to tackle protein misfolding diseases

25 January 2019

Wren Therapeutics secures £18 million in funding to tackle protein misfolding diseases A biopharmaceutical company set-up by Cambridge academics from St John's College to develop drugs to treat illnesses such as Alzheimer's, Parkinson’s and more than 50 other related diseases has won £18 million in a Series A financing...

Read more


Read more at: Open Access to Drug Discovery

Open Access to Drug Discovery

The folllowing companies and not-for-profit organisations offer services and tools which support drug discovery. AstraZeneca BioAscent EMBL-EBI EU-OPENSCREEN GSK UCB AstraZeneca AstraZeneca have a number of offerings under their OpenInnovation platform including: Clinical Compound Bank Preclinical Toolbox Target Innovation...

Read more


Latest news

New approach to drug discovery could lead to personalised treatment of neuropsychiatric disorders

9 May 2019

Researchers have developed a method that could drastically accelerate the search for new drugs to treat mental health disorders such as schizophrenia. Psychiatric disorders are increasingly recognised as disorders of the whole body Sabine Bahn Mental health disorders are the leading cause of disability worldwide...

Cambridge spin-out PolyProx Therapeutics raises £3.4m seed financing

2 May 2019

PolyProx Therapeutics, a new biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announced that it has raised £3.4m of seed capital. A spin-out of the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a...

‘Fingerprint database’ could help scientists to identify new cancer culprits

30 April 2019

Scientists in Cambridge and London have developed a catalogue of DNA mutation ‘fingerprints’ that could help doctors pinpoint the environmental culprit responsible for a patient’s tumour – including showing some of the fingerprints left in lung tumours by specific chemicals found in tobacco smoke. Mutational signatures...